Isotechnika

Contact
isotechnika.com
+1780487-1600

Isotechnika Inc.

5120 - 75th Street
T6E 6W2 Edmonton
Canada

Phone

isotechnika.com
Contact
Profile News
Contact

About Isotechnika

Isotechnika Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of novel immunosuppressive therapeutics for the treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. In addition to the Company’s drug pipeline, Isotechnika also has diagnostic products.

Read more about Isotechnika
Facts about Isotechnika
  • Focus : Manufacturer
  • Industry : Pharma

News about Isotechnika

Isotechnika

10-Jan-2012 | people

Isotechnika Announces Changes to Senior Management and Board of Directors

Isotechnika Pharma Inc. announced a number of changes to its senior management and Board of Directors.Mr. Daniel Park has resigned as Chief Business ...

Read news
Isotechnika

03-Nov-2009 | research and development

Isotechnika Pharma develops portfolio of non-immunosuppressive cyclosporine analogue molecules (NICAMs)

Isotechnika Pharma Inc. announced that it has developed a portfolio of non-immunosuppressive cyclosporine analogue molecules (NICAMs) with potent ...

Read news
Isotechnika

17-Aug-2009 | people

Isotechnika Pharma appoints Dr. Jurgen Engel to Board of Directors

Isotechnika Pharma Inc. announced that it has appointed Dr. Jurgen Engel to its Board of Directors. Dr. Engel is currently the President and CEO of AEterna ...

Read news
Isotechnika

22-Jun-2009 | business & finance

Isotechnika Pharma announces the closing of its partnership with Paladin Labs

Isotechnika Pharma Inc. announced that the previously announced court supervised plan of arrangement with Paladin Labs Inc. has been completed. The ...

Read news
Isotechnika

21-Apr-2008 | research and development

Isotechnika's Canadian Phase 3 psoriasis trial published

Isotechnika Inc. announced that The Lancet will publish an article titled "Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind ...

Read news
Isotechnika

07-Dec-2007 | research and development

Isotechnika Inc. granted patent for mTOR inhibitor

Isotechnika Inc. announced that the process of nationalizing European Patent No. 1644392 has commenced with the issuance of a Swedish Patent for its mTOR ...

Read news
Isotechnika

26-Nov-2007 | research and development

Isotechnika Inc. completes critical study

Isotechnika Inc. announced the results from the rat carcinogenicity study for its lead immunosuppressive drug, ISA247. ISA247 did not exhibit any ...

Read news
Isotechnika

09-Aug-2007 | research and development

Isotechnika's lead drug, ISA247, receives fast track designation from FDA for the treatment of uveitis

Isotechnika announced that the Food and Drug Administration (FDA) of the United States granted fast track designation for the Company's lead drug, ISA247 ...

Read news
Show more news about Isotechnika

Here you will find Isotechnika Inc.